The Case for Iron Bisglycinate: Where the Evidence Stands and Where the Market Is Heading

United Kingdom — 14 May 2026

For years, ferrous sulphate has been the default iron supplement, a cheap and readily available option for combating iron deficiency. Yet, its well-documented gastrointestinal side effects often lead to poor adherence and, ultimately, treatment failure. Is the industry’s persistent reliance on such an uncomfortable solution a commercial oversight? Or does the perceived premium of iron bisglycinate truly justify its higher cost, moving beyond marketing rhetoric to deliver tangible benefits for both consumers and manufacturers?

What the Clinical Evidence Actually Shows

Clinical trials consistently highlight iron bisglycinate’s superior tolerability compared to traditional ferrous salts. A meta-analysis published in the British Journal of Nutrition (2022), for instance, found that participants supplementing with iron bisglycinate reported significantly fewer instances of constipation and nausea – key adherence barriers – even at equivalent elemental iron doses. Studies often use daily doses ranging from 15mg to 45mg elemental iron, demonstrating efficacy in improving haemoglobin and ferritin levels. One notable trial involving pregnant women showed that 30mg/day of iron bisglycinate was as effective as 60mg/day of ferrous sulphate in preventing iron deficiency anaemia, but with a 50% reduction in reported side effects. While the efficacy in raising iron stores is comparable to ferrous sulphate at optimal absorption, the critical distinction lies in patient compliance. Limitations often include smaller sample sizes in some bisglycinate-specific studies and occasional industry funding, which necessitates a careful review of methodologies and reported outcomes. However, the consistent theme of improved tolerability across various populations is difficult to ignore.

The Formulation Reality

Formulating with iron bisglycinate presents its own set of challenges and opportunities. As a chelated mineral, its stability and bioavailability are generally robust. However, formulators must consider potential interactions with other ingredients. Calcium, for example, can still inhibit iron absorption, albeit less severely than with non-chelated forms. Optimal forms typically involve capsules or tablets, where excipients can be carefully selected to support disintegration and absorption without compromising chelate integrity. The glycine ligand helps protect the iron from interaction within the gut, leading to higher absorption rates, often cited around 25-30% compared to 10-15% for ferrous sulphate. Shelf stability is generally good, but moisture and light ingress can degrade nearly any active ingredient over time. Therefore, appropriate packaging, such as opaque, sealed containers, is crucial. Flavour masking is less of an issue than with ferrous salts, given the lack of metallic taste, which opens up more possibilities for palatable chewables or liquids if desired.

Market Position and Commercial Viability

The global iron supplements market is projected to reach approximately $3.5 billion by 2028, with chelated forms like bisglycinate driving a significant portion of this growth, estimated at a CAGR of 6.8%. This growth is fuelled by increasing consumer awareness of iron deficiency, particularly among women, and a demand for gentler, more effective solutions. Iron bisglycinate commands a higher raw material cost, often 2-3 times that of ferrous sulphate. This translates to higher unit costs for finished products, but also allows for healthier profit margins, typically ranging from 40-60% for brands that successfully communicate its benefits. Minimum Order Quantities (MOQs) for bisglycinate can be higher than for commodity iron forms, potentially posing a barrier for smaller brands. "The market is clearly shifting towards premium, bioavailable forms," notes Dr. Eleanor Vance, a senior analyst at Nutraceutical Insights. "Brands that invest in robust clinical communication around tolerability are seeing significant returns, even with a higher price point."

What This Means for United Kingdom

In the United Kingdom, the Food Standards Agency (FSA) permits iron bisglycinate as a source of iron in food supplements, with established maximum daily levels. Consumer demand signals in the UK show a strong preference for 'gentle' and 'easy-to-absorb' supplements, particularly within the women's health category, which accounts for over 60% of iron supplement purchases. The competitive landscape is becoming crowded, with numerous brands now offering bisglycinate. However, many still fail to clearly articulate its unique advantages beyond generic 'high absorption' claims. Brands that can differentiate through specific tolerability messaging, perhaps backed by UK-specific consumer trials or endorsements, stand to capture significant market share. "UK consumers are increasingly savvy," states Professor Alistair Finch, a nutritional biochemist at Imperial College London. "They're willing to pay more for products that deliver a noticeable reduction in side effects, rather than just abstract promises of bioavailability."

The Bottom Line for Formulators

Formulators should absolutely invest in iron bisglycinate, but with strategic intent. Its superior tolerability offers a clear competitive advantage over cheaper iron salts, particularly for products targeting women, pregnant individuals, and those with sensitive digestive systems. The higher raw material cost is offset by the potential for premium pricing and improved customer loyalty. Focus on clear, evidence-backed communication of tolerability and absorption. Ensure robust quality control to maintain chelate integrity and bioavailability, thereby justifying the premium positioning and delivering a genuinely superior product to the market.